ArticlePloS one2010

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

David M Lucas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.